STRS OHIO - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.

Quarter-by-quarter ownership
STRS OHIO ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,528
+0.4%
40,000
-5.2%
0.01%
+16.7%
Q2 2023$1,522
-56.0%
42,200
-53.4%
0.01%
+20.0%
Q1 2023$3,459
+129.5%
90,600
+241.9%
0.01%
-28.6%
Q4 2022$1,507
-99.9%
26,500
-39.8%
0.01%
-12.5%
Q3 2022$1,739,000
+48.6%
44,000
+65.4%
0.01%
+60.0%
Q2 2022$1,170,000
+30.4%
26,600
+18.2%
0.01%
+66.7%
Q1 2022$897,000
-56.6%
22,500
-56.2%
0.00%
-57.1%
Q4 2021$2,066,000
+3.9%
51,400
+5.1%
0.01%0.0%
Q3 2021$1,989,000
-10.4%
48,9000.0%0.01%
-12.5%
Q2 2021$2,220,000
+206.2%
48,900
+181.0%
0.01%
+166.7%
Q1 2021$725,000
-6.7%
17,400
-4.4%
0.00%0.0%
Q4 2020$777,000
+79.4%
18,200
+10.3%
0.00%
+50.0%
Q3 2020$433,000
-5.5%
16,500
-3.5%
0.00%0.0%
Q2 2020$458,000
-3.8%
17,100
-35.5%
0.00%
-33.3%
Q1 2020$476,000
-59.2%
26,500
-59.8%
0.00%
-40.0%
Q4 2019$1,168,000
-46.3%
65,900
-53.0%
0.01%0.0%
Q3 2019$2,174,000
+80.6%
140,200
+100.0%
0.01%0.0%
Q2 2019$1,204,000
+12.2%
70,100
+5.1%
0.01%0.0%
Q1 2019$1,073,000
+10.1%
66,7000.0%0.01%0.0%
Q4 2018$975,000
-18.1%
66,700
+1.7%
0.01%0.0%
Q3 2018$1,191,000
+7.7%
65,6000.0%0.01%0.0%
Q2 2018$1,106,000
+1216.7%
65,600
+1425.6%
0.01%
Q1 2018$84,000
+10.5%
4,300
+13.2%
0.00%
Q4 2017$76,0003,8000.00%
Q1 2016$0
-100.0%
0
-100.0%
0.00%
Q4 2015$105,000
-41.0%
6,100
-54.1%
0.00%
-100.0%
Q3 2015$178,000
+36.9%
13,300
+129.3%
0.00%0.0%
Q2 2015$130,0005,8000.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders